TLE3 and cancer: The mPEG-b-P (Glu-co-Phe)-based drug delivery system allows the rapid release of GRg3 from nanoparticles to target cancer cells, reduces the expression of nuclear antigens in proliferating cells, significantly inhibits CRC proliferation, and leads to CRC apoptosis by increasing the expression of caspase-3 (Qiu et al., 2019).